Loading ......
Filter By Product Search for
FBLN5
FBLN5 Full Name
fibulin 5
FBLN5 Introduction
Fibulin 5 was isolated independently by several groups and therefore carries a series of colourful aliases, among them DANCE, EVEC and urine p50 protein. The gene is located at 14q32.12 and encodes a secreted glycoprotein of about 50 kDa that begins with an atypical integrin-binding RGD motif, followed by an anaphylatoxin-like module and a tandem array of six calcium-binding epidermal growth factor repeats ending in a fibulin-type carboxy-terminal domain. FBLN5 is produced by fibroblasts, smooth muscle cells and endothelial cells, and it accumulates in the extracellular matrix of elastic tissues, where it associates with tropoelastin, fibrillin-1 and lysyl oxidase-like 1.
Figure 1. The structure of FBLN5.
Elastic Fibre Assembly and Matrix Scaffolding
Elastic fibres are assembled on a microfibrillar scaffold, and FBLN5 acts as the essential adaptor that brings tropoelastin monomers into register and orientates the crosslinking enzyme LOXL1. In its absence, elastin is deposited as disorganised aggregates rather than as functional fibres, and the resulting vessels and skin lose recoil. The integrin-binding RGD motif allows FBLN5 to connect the matrix to cell-surface alpha-5-beta-1 and alpha-v-beta-3 integrins, transducing mechanical signals that regulate smooth muscle quiescence and endothelial survival. The protein also antagonises angiogenesis by competing with fibronectin for integrin occupancy and by inhibiting endothelial proliferation.
Cutis Laxa, Macular Degeneration and Vascular Disease
Biallelic FBLN5 mutations cause autosomal recessive cutis laxa type IA, a connective tissue disorder marked by loose, inelastic skin, pulmonary emphysema and aortic tortuosity, while heterozygous variants have been associated with age-related macular degeneration, where defective elastic laminae in Bruch membrane predispose to drusen formation. In the vasculature, reduced FBLN5 accelerates arterial stiffening and neointimal thickening after injury, and the protein is downregulated in atherosclerotic plaques. In cancer, FBLN5 is frequently silenced in breast and lung carcinoma; its re-expression suppresses tumour angiogenesis and metastasis, making the gene an attractive candidate for matrix-targeted therapy.
Alternate Names for FBLN5
FBLN5; fibulin 5; EVEC; UP50; ADCL2; ARMD3; DANCE; ARCL1A; FIBL-5; fibulin-5; urine p50 protein; developmental arteries and neural crest EGF-like protein;
Loading ......